TCT-172 Clinical Outcome of Complex Patients Treated With Second-Generation Zotarolimus-Eluting Resolute vs. Everolimus-Eluting Xience V Stents: Insight From 2-Year Follow-up of TWENTE

Hanim Sen, Kenneth Tandjung, Ming Kai Lam, Mounir W. Basalus, Martin G. Stoel, Frits de Man, Hans W. Louwerenburg, Gert K. van Houwelingen, Gerard C.M. Linssen, Mark B. Nienhuis, Job van der Palen, Clemens von Birgelen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Contemporary second-generation drug-eluting stents (DES) are often used in complex patients, but there is limited knowledge about potential difference in outcome between the zotarolimus-eluting Resolute and everolimus-eluting Xience V stents in these patients.

Methods: We therefore analyzed the 2-year clinical outcome data of 1033 complex TWENTE trial patients treated with second-generation everolimus-eluting Xience V or zotarolimus-eluting Resolute stents. The primary endpoint of the TWENTE trial, target vessel failure, was defined as cardiac death, target vessel-related myocardial infarction (MI), or target vessel revascularization (TVR).

Results: Among the 1033 complex patients, 529 (51.2%) were treated with Resolute stents and 504 (48.8%) with Xience V. Patient and procedure-related characteristics were similar between DES groups. After 2-year follow-up, clinical outcome was also similar between DES groups. In patients treated with Resolute and Xience V, TVF occurred in 12.1% and 12.3% of patients, respectively. In addition, DES groups did not differ in cardiac death, MI, or TVR, the individual components of TVF.

Conclusions: Complex patients treated with zotarolimus-eluting Resolute and everolimus-eluting Xience V stents showed similar safety and efficacy during 2-year follow-up.
Original languageEnglish
Pages (from-to)B55-B55
JournalJournal of the American College of Cardiology
Volume62
Issue number18, Suppl. 1
DOIs
Publication statusPublished - 2013
Event23rd Annual Scientific Symposium of Transcatheter Cardiovascular Therapeutics, TCT 2011 - San Francisco, United States
Duration: 7 Nov 201111 Nov 2011
Conference number: 23

Keywords

  • METIS-302486
  • IR-89481

Fingerprint Dive into the research topics of 'TCT-172 Clinical Outcome of Complex Patients Treated With Second-Generation Zotarolimus-Eluting Resolute vs. Everolimus-Eluting Xience V Stents: Insight From 2-Year Follow-up of TWENTE'. Together they form a unique fingerprint.

Cite this